nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—Electrolyte imbalance—Hydrochlorothiazide—nephrolithiasis	0.041	0.0907	CcSEcCtD
Dexmedetomidine—Ventricular arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.0231	0.0512	CcSEcCtD
Dexmedetomidine—Gamma-glutamyltransferase increased—Hydrochlorothiazide—nephrolithiasis	0.0208	0.0461	CcSEcCtD
Dexmedetomidine—CYP1A2—urine—nephrolithiasis	0.0178	0.144	CbGeAlD
Dexmedetomidine—Ventricular tachycardia—Hydrochlorothiazide—nephrolithiasis	0.0171	0.0379	CcSEcCtD
Dexmedetomidine—Hyperkalaemia—Hydrochlorothiazide—nephrolithiasis	0.0168	0.0372	CcSEcCtD
Dexmedetomidine—Wheezing—Hydrochlorothiazide—nephrolithiasis	0.0166	0.0368	CcSEcCtD
Dexmedetomidine—Blood urea increased—Hydrochlorothiazide—nephrolithiasis	0.0162	0.0358	CcSEcCtD
Dexmedetomidine—CYP2E1—urine—nephrolithiasis	0.0161	0.13	CbGeAlD
Dexmedetomidine—Pulmonary oedema—Hydrochlorothiazide—nephrolithiasis	0.0153	0.0337	CcSEcCtD
Dexmedetomidine—Atrial fibrillation—Hydrochlorothiazide—nephrolithiasis	0.0131	0.029	CcSEcCtD
Dexmedetomidine—Thirst—Hydrochlorothiazide—nephrolithiasis	0.0131	0.0289	CcSEcCtD
Dexmedetomidine—ADRA1D—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0128	0.0302	CbGpPWpGaD
Dexmedetomidine—CYP2D6—urine—nephrolithiasis	0.0127	0.103	CbGeAlD
Dexmedetomidine—ADRA2B—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0116	0.0273	CbGpPWpGaD
Dexmedetomidine—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.0113	0.025	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.0112	0.0248	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.011	0.0243	CcSEcCtD
Dexmedetomidine—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.0108	0.0239	CcSEcCtD
Dexmedetomidine—ADRA2C—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0108	0.0255	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0108	0.0254	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0106	0.0251	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00973	0.0229	CbGpPWpGaD
Dexmedetomidine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00972	0.0229	CbGpPWpGaD
Dexmedetomidine—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.0097	0.0215	CcSEcCtD
Dexmedetomidine—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.00964	0.0213	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.00945	0.0209	CcSEcCtD
Dexmedetomidine—ADRA1B—renal system—nephrolithiasis	0.0094	0.076	CbGeAlD
Dexmedetomidine—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.0094	0.0208	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.0094	0.0208	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00932	0.0206	CcSEcCtD
Dexmedetomidine—ADRA2C—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00909	0.0214	CbGpPWpGaD
Dexmedetomidine—ADRA1B—kidney—nephrolithiasis	0.00909	0.0734	CbGeAlD
Dexmedetomidine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00903	0.0213	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00894	0.0211	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00878	0.0207	CbGpPWpGaD
Dexmedetomidine—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00876	0.0194	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00848	0.0187	CcSEcCtD
Dexmedetomidine—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00829	0.0183	CcSEcCtD
Dexmedetomidine—ADRA1D—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00786	0.0185	CbGpPWpGaD
Dexmedetomidine—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00769	0.017	CcSEcCtD
Dexmedetomidine—ADRA2A—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00738	0.0174	CbGpPWpGaD
Dexmedetomidine—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00692	0.0153	CcSEcCtD
Dexmedetomidine—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00688	0.0152	CcSEcCtD
Dexmedetomidine—ADRA1B—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00652	0.0154	CbGpPWpGaD
Dexmedetomidine—SLC6A2—NRF2 pathway—SLC2A9—nephrolithiasis	0.00651	0.0154	CbGpPWpGaD
Dexmedetomidine—SLC6A2—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00637	0.015	CbGpPWpGaD
Dexmedetomidine—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00635	0.0141	CcSEcCtD
Dexmedetomidine—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00624	0.0138	CcSEcCtD
Dexmedetomidine—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00616	0.0136	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00599	0.0132	CcSEcCtD
Dexmedetomidine—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00597	0.0132	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00591	0.0131	CcSEcCtD
Dexmedetomidine—SLC6A2—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00583	0.0137	CbGpPWpGaD
Dexmedetomidine—SLC6A2—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00583	0.0137	CbGpPWpGaD
Dexmedetomidine—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00571	0.0126	CcSEcCtD
Dexmedetomidine—ADRA1D—GPCRs, Other—CHRM3—nephrolithiasis	0.00569	0.0134	CbGpPWpGaD
Dexmedetomidine—ADRA2C—nephron tubule—nephrolithiasis	0.00554	0.0447	CbGeAlD
Dexmedetomidine—ADRA2C—Regulation of insulin secretion—CHRM3—nephrolithiasis	0.00549	0.0129	CbGpPWpGaD
Dexmedetomidine—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00545	0.0121	CcSEcCtD
Dexmedetomidine—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00543	0.012	CcSEcCtD
Dexmedetomidine—Pain—Hydrochlorothiazide—nephrolithiasis	0.00523	0.0116	CcSEcCtD
Dexmedetomidine—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00523	0.0116	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00504	0.0111	CcSEcCtD
Dexmedetomidine—ADRA2C—renal system—nephrolithiasis	0.00503	0.0407	CbGeAlD
Dexmedetomidine—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.005	0.0111	CcSEcCtD
Dexmedetomidine—ADRA2B—G alpha (i) signalling events—RGS14—nephrolithiasis	0.00493	0.0116	CbGpPWpGaD
Dexmedetomidine—ADRA2C—kidney—nephrolithiasis	0.00486	0.0393	CbGeAlD
Dexmedetomidine—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00483	0.0107	CcSEcCtD
Dexmedetomidine—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00483	0.0107	CcSEcCtD
Dexmedetomidine—ADRA2C—cortex of kidney—nephrolithiasis	0.00474	0.0383	CbGeAlD
Dexmedetomidine—ADRA2C—G alpha (i) signalling events—RGS14—nephrolithiasis	0.0046	0.0109	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Regulation of insulin secretion—CHRM3—nephrolithiasis	0.00446	0.0105	CbGpPWpGaD
Dexmedetomidine—ADRA1D—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00443	0.0104	CbGpPWpGaD
Dexmedetomidine—SLC6A2—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00441	0.0104	CbGpPWpGaD
Dexmedetomidine—SLC6A2—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00441	0.0104	CbGpPWpGaD
Dexmedetomidine—CYP1A2—renal system—nephrolithiasis	0.00437	0.0353	CbGeAlD
Dexmedetomidine—CYP2E1—nephron tubule—nephrolithiasis	0.00432	0.0349	CbGeAlD
Dexmedetomidine—ADRA2C—Integration of energy metabolism—CHRM3—nephrolithiasis	0.00432	0.0102	CbGpPWpGaD
Dexmedetomidine—CYP1A1—renal system—nephrolithiasis	0.00431	0.0348	CbGeAlD
Dexmedetomidine—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00418	0.00925	CcSEcCtD
Dexmedetomidine—CYP1A1—kidney—nephrolithiasis	0.00416	0.0336	CbGeAlD
Dexmedetomidine—SLC6A2—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.0041	0.00968	CbGpPWpGaD
Dexmedetomidine—SLC6A2—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.0041	0.00968	CbGpPWpGaD
Dexmedetomidine—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00404	0.00894	CcSEcCtD
Dexmedetomidine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00396	0.00933	CbGpPWpGaD
Dexmedetomidine—CYP2E1—renal system—nephrolithiasis	0.00393	0.0317	CbGeAlD
Dexmedetomidine—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00389	0.0086	CcSEcCtD
Dexmedetomidine—Rash—Hydrochlorothiazide—nephrolithiasis	0.00385	0.00853	CcSEcCtD
Dexmedetomidine—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00385	0.00852	CcSEcCtD
Dexmedetomidine—ADRA1D—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.00384	0.00905	CbGpPWpGaD
Dexmedetomidine—Headache—Hydrochlorothiazide—nephrolithiasis	0.00383	0.00847	CcSEcCtD
Dexmedetomidine—CYP2E1—kidney—nephrolithiasis	0.0038	0.0307	CbGeAlD
Dexmedetomidine—ADRA2A—cortex of kidney—nephrolithiasis	0.00378	0.0305	CbGeAlD
Dexmedetomidine—ADRA2A—G alpha (i) signalling events—RGS14—nephrolithiasis	0.00374	0.00881	CbGpPWpGaD
Dexmedetomidine—CYP2E1—cortex of kidney—nephrolithiasis	0.0037	0.0299	CbGeAlD
Dexmedetomidine—ADRA1B—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00367	0.00866	CbGpPWpGaD
Dexmedetomidine—SLC6A2—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00366	0.00862	CbGpPWpGaD
Dexmedetomidine—SLC6A2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00363	0.00856	CbGpPWpGaD
Dexmedetomidine—SLC6A2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00363	0.00856	CbGpPWpGaD
Dexmedetomidine—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00363	0.00803	CcSEcCtD
Dexmedetomidine—ADRA2A—Integration of energy metabolism—CHRM3—nephrolithiasis	0.00351	0.00826	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.0035	0.00824	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Phase II conjugation—SLC26A1—nephrolithiasis	0.00343	0.00809	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Biological oxidations—SLC26A1—nephrolithiasis	0.00334	0.00787	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00329	0.00775	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.00327	0.0077	CbGpPWpGaD
Dexmedetomidine—SLC6A2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00324	0.00763	CbGpPWpGaD
Dexmedetomidine—ADRA1D—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.0032	0.00754	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.00319	0.00751	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Biological oxidations—SLC26A1—nephrolithiasis	0.00315	0.00742	CbGpPWpGaD
Dexmedetomidine—CYP2D6—renal system—nephrolithiasis	0.00311	0.0251	CbGeAlD
Dexmedetomidine—CYP2D6—kidney—nephrolithiasis	0.00301	0.0243	CbGeAlD
Dexmedetomidine—SLC6A2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00296	0.00698	CbGpPWpGaD
Dexmedetomidine—SLC6A2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00296	0.00698	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00286	0.00675	CbGpPWpGaD
Dexmedetomidine—ADRA1B—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00266	0.00626	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.00265	0.00625	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00247	0.00583	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00238	0.0056	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.00237	0.00559	CbGpPWpGaD
Dexmedetomidine—SLC6A2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00224	0.00529	CbGpPWpGaD
Dexmedetomidine—SLC6A2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00224	0.00529	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00223	0.00527	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00212	0.005	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00209	0.00492	CbGpPWpGaD
Dexmedetomidine—SLC6A2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00209	0.00492	CbGpPWpGaD
Dexmedetomidine—SLC6A2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00209	0.00492	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00205	0.00484	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Biological oxidations—SLC26A1—nephrolithiasis	0.00201	0.00473	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00191	0.00451	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—RGS14—nephrolithiasis	0.00187	0.0044	CbGpPWpGaD
Dexmedetomidine—SLC6A2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00186	0.00438	CbGpPWpGaD
Dexmedetomidine—SLC6A2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00186	0.00438	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—SLC7A9—nephrolithiasis	0.0018	0.00425	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—DGKH—nephrolithiasis	0.0018	0.00425	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00179	0.00421	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00176	0.00415	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—RGS14—nephrolithiasis	0.0017	0.004	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00169	0.00399	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—RGS14—nephrolithiasis	0.00169	0.00398	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—SLC7A9—nephrolithiasis	0.00168	0.00397	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—DGKH—nephrolithiasis	0.00168	0.00397	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR ligand binding—CHRM3—nephrolithiasis	0.00161	0.00381	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—RGS14—nephrolithiasis	0.00158	0.00371	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—RGS14—nephrolithiasis	0.00155	0.00365	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—RGS14—nephrolithiasis	0.00153	0.00361	CbGpPWpGaD
Dexmedetomidine—SLC6A2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00149	0.0035	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR ligand binding—PTH—nephrolithiasis	0.00148	0.00348	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR ligand binding—CHRM3—nephrolithiasis	0.00146	0.00344	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00145	0.00342	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—RGS14—nephrolithiasis	0.00143	0.00337	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—RGS14—nephrolithiasis	0.00141	0.00332	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—SLC7A9—nephrolithiasis	0.00137	0.00322	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—DGKH—nephrolithiasis	0.00137	0.00322	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR ligand binding—CHRM3—nephrolithiasis	0.00136	0.00321	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR ligand binding—CHRM3—nephrolithiasis	0.00134	0.00316	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR ligand binding—PTH—nephrolithiasis	0.00133	0.00314	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—RGS14—nephrolithiasis	0.00128	0.00302	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—DGKH—nephrolithiasis	0.00126	0.00297	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR ligand binding—PTH—nephrolithiasis	0.00124	0.00293	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR ligand binding—PTH—nephrolithiasis	0.00123	0.00289	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—ADCY10—nephrolithiasis	0.00118	0.00278	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—RGS14—nephrolithiasis	0.00116	0.00274	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—DGKH—nephrolithiasis	0.00115	0.0027	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—DGKH—nephrolithiasis	0.00114	0.00269	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR ligand binding—CHRM3—nephrolithiasis	0.00111	0.00261	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—DGKH—nephrolithiasis	0.00106	0.00251	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—ADCY10—nephrolithiasis	0.00106	0.00251	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—DGKH—nephrolithiasis	0.00105	0.00247	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—DGKH—nephrolithiasis	0.00103	0.00244	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR ligand binding—PTH—nephrolithiasis	0.00101	0.00238	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—GRHPR—nephrolithiasis	0.00101	0.00238	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—RGS14—nephrolithiasis	0.001	0.00236	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ADCY10—nephrolithiasis	0.000994	0.00234	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ADCY10—nephrolithiasis	0.000978	0.00231	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—DGKH—nephrolithiasis	0.000966	0.00228	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—DGKH—nephrolithiasis	0.000951	0.00224	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000912	0.00215	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—RGS14—nephrolithiasis	0.000905	0.00213	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—AGXT—nephrolithiasis	0.000901	0.00212	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—DGKH—nephrolithiasis	0.000864	0.00204	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—RGS14—nephrolithiasis	0.000845	0.00199	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—PTH—nephrolithiasis	0.000834	0.00197	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—RGS14—nephrolithiasis	0.000832	0.00196	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—CHRM3—nephrolithiasis	0.000828	0.00195	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000823	0.00194	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—GRHPR—nephrolithiasis	0.000821	0.00193	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ADCY10—nephrolithiasis	0.000807	0.0019	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—DGKH—nephrolithiasis	0.000785	0.00185	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000769	0.00181	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—APRT—nephrolithiasis	0.000766	0.00181	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—SLC26A1—nephrolithiasis	0.000766	0.00181	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—PTH—nephrolithiasis	0.000758	0.00179	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000757	0.00178	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—GRHPR—nephrolithiasis	0.000754	0.00178	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—PTH—nephrolithiasis	0.000753	0.00178	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—CHRM3—nephrolithiasis	0.000748	0.00176	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—AGXT—nephrolithiasis	0.000732	0.00172	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—GRHPR—nephrolithiasis	0.000711	0.00168	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—PTH—nephrolithiasis	0.000704	0.00166	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—CHRM3—nephrolithiasis	0.000699	0.00165	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—PTH—nephrolithiasis	0.000692	0.00163	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—CHRM3—nephrolithiasis	0.000687	0.00162	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—RGS14—nephrolithiasis	0.000686	0.00162	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—PTH—nephrolithiasis	0.000684	0.00161	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—DGKH—nephrolithiasis	0.000677	0.0016	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000677	0.0016	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—AGXT—nephrolithiasis	0.000672	0.00158	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—PTH—nephrolithiasis	0.000639	0.00151	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—AGXT—nephrolithiasis	0.000633	0.00149	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—PTH—nephrolithiasis	0.000629	0.00148	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000625	0.00147	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—SLC26A1—nephrolithiasis	0.000622	0.00147	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—APRT—nephrolithiasis	0.000622	0.00147	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000611	0.00144	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—DGKH—nephrolithiasis	0.000611	0.00144	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—PTH—nephrolithiasis	0.000571	0.00135	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—SLC26A1—nephrolithiasis	0.000571	0.00135	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—APRT—nephrolithiasis	0.000571	0.00135	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—DGKH—nephrolithiasis	0.000571	0.00135	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000571	0.00135	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—CHRM3—nephrolithiasis	0.000567	0.00134	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000562	0.00132	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—DGKH—nephrolithiasis	0.000562	0.00132	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—AQP1—nephrolithiasis	0.000546	0.00129	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—SLC26A1—nephrolithiasis	0.000539	0.00127	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—APRT—nephrolithiasis	0.000539	0.00127	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GRHPR—nephrolithiasis	0.000535	0.00126	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—PTH—nephrolithiasis	0.000519	0.00122	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—CHRM3—nephrolithiasis	0.000493	0.00116	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CHRM3—nephrolithiasis	0.000489	0.00115	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—AGXT—nephrolithiasis	0.000477	0.00112	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—DGKH—nephrolithiasis	0.000464	0.00109	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000464	0.00109	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GRHPR—nephrolithiasis	0.000453	0.00107	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PTH—nephrolithiasis	0.000448	0.00106	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—AQP1—nephrolithiasis	0.000443	0.00104	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CHRM3—nephrolithiasis	0.000442	0.00104	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CHRM3—nephrolithiasis	0.000413	0.000973	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—AQP1—nephrolithiasis	0.000407	0.00096	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CHRM3—nephrolithiasis	0.000406	0.000957	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	0.000405	0.000956	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—APRT—nephrolithiasis	0.000405	0.000956	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PTH—nephrolithiasis	0.000404	0.000953	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—AGXT—nephrolithiasis	0.000404	0.000952	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—CHRM3—nephrolithiasis	0.000401	0.000945	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—AQP1—nephrolithiasis	0.000384	0.000905	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PTH—nephrolithiasis	0.000377	0.00089	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PTH—nephrolithiasis	0.000371	0.000876	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CHRM3—nephrolithiasis	0.000368	0.000868	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CHRM3—nephrolithiasis	0.000347	0.000818	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—APRT—nephrolithiasis	0.000343	0.00081	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—SLC26A1—nephrolithiasis	0.000343	0.00081	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CHRM3—nephrolithiasis	0.000335	0.00079	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PTH—nephrolithiasis	0.000307	0.000723	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—AQP1—nephrolithiasis	0.000289	0.000681	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CHRM3—nephrolithiasis	0.000261	0.000616	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—AQP1—nephrolithiasis	0.000245	0.000577	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—SPP1—nephrolithiasis	0.000225	0.00053	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CHRM3—nephrolithiasis	0.000221	0.000522	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—SPP1—nephrolithiasis	0.000203	0.000478	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—SPP1—nephrolithiasis	0.000189	0.000447	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—SPP1—nephrolithiasis	0.000186	0.00044	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SPP1—nephrolithiasis	0.000154	0.000363	CbGpPWpGaD
